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Transcriptional Regulation of the Bmp2 Gene
RETINOIC ACID INDUCTION IN F9 EMBRYONAL CARCINOMA CELLS AND SACCHAROMYCES CEREVISIAE*
(Received for publication, July 6, 1998, and in revised form, October 20, 1998)
Loreé C. Heller‡, Yong Li‡, Kevin L. Abrams‡, and Melissa B. Rogers‡§¶i
From the Departments of ‡Biology and §Pharmacology and the ¶Institute for Biomolecular Science, University of South
Florida, Tampa, Florida 33620
Bmp2, a highly conserved member of the transforming
growth factor-b gene family, is crucial for normal devel-
opment. Retinoic acid, combined with cAMP analogs,
sharply induces the Bmp2 mRNA during the differenti-
ation of F9 embryonal carcinoma cells into parietal
endoderm. Retinoic acid (RA) also induces the Bmp2
gene in chick limb buds. Since normal Bmp2 expression
may require an endogenous retinoid signal and aber-
rant Bmp2 expression may cause some aspects of RA-
induced teratogenesis, we studied the mechanism un-
derlying the induction of Bmp2. Measurements of the
Bmp2 mRNA half-life and nuclear run-on assays indi-
cated that RA stimulated the transcription rate of the
Bmp2 gene. The results of ribonuclease protection and
primer extension assays indicated that Bmp2 transcrip-
tion started 2,127 nucleotides upstream of the transla-
tion start site in F9 cells. To identify genetic elements
controlling this transcription rate increase, upstream
and downstream genomic sequences flanking the Bmp2
gene were screened using chloramphenicol acetyltrans-
ferase reporter genes in F9 cells and b-galactosidase
reporter genes in Saccharomyces cerevisiae that were
cotransformed with retinoic acid receptor and retinoid
X receptor expression plasmids. RA-dependent tran-
scriptional activation was detected between base pairs
22,373 and 22,316 relative to the translation start site.
We also identified a required Sp1 binding site between
22,308 and 22,298. The data indicate that Bmp2 is di-
rectly regulated by retinoic acid-bound receptors and
Sp1.
Bone morphogenetic proteins (BMPs)1 are developmentally
critical growth factors of the transforming growth factor-b fam-
ily that were first described as having osteogenic activity in
rats (1–3). Bmp2 and Bmp4 transcripts are widely expressed in
vertebrate embryonic structures undergoing induction and
morphogenesis (4–6). BMP signaling is involved in key embry-
onic processes such as epithelio-mesenchymal interactions (5),
interdigital apoptosis in the developing limb (7), and dorsal-
ventral axis specification (8). Mice having null mutations in the
Bmp2 or Bmp4 (9, 10) or the Bmp receptor IA (11) genes die
during early embryogenesis. The phenotypes of these mutants
prove that BMP signaling is required for numerous extraem-
bryonic and embryonic developmental processes.
The evolutionary conservation of the Bmp2 and Bmp4 genes
and their Drosophila homolog dpp is remarkable. Conservation
exists at both the functional and sequence levels (8, 12–14).
Both BMP2 in mouse and DPP in Drosophila have pleiotropic
functions and are expressed in a highly tissue- and stage-
specific manner. Multiple promoters and alternative splicing
produce three major and several minor dpp transcripts (15).
Our work in murine cells and the Drosophila studies indicate
that the multiple core promoters are closely involved in Bmp2
and dpp tissue-specific regulation. It is likely that the regula-
tion of this essential growth factor in mammals equals the
complexity of dpp regulation in Drosophila.
Many Bmp2-expressing tissues develop abnormally in vitamin
A-deficient embryos or after exposure to the potent teratogen
retinoic acid (RA). These include the heart and cardiovascula-
ture, limbs, central nervous system, craniofacial structures, and
vertebrae (see Refs. 3 and 16 and references therein). The first
indication that the Bmp2 gene was regulated by RA was the
discovery that it was strongly induced in F9 embryonal carci-
noma cells stimulated to differentiate with RA (17). Subse-
quently, the Bmp2 gene was found to be induced by RA in the
developing chick limb (18). Since retinoid signaling may con-
tribute to the normal pattern of embryonic Bmp2 expression
and since the aberrant induction of Bmp2 by excess RA may
cause some RA-associated deformities, elucidating the genetic
regulatory elements controlling the RA inducibility of Bmp2
will increase our understanding of normal development and
teratogenesis.
F9 cells, a widely used model of cellular differentiation and
early embryonic development, are an excellent biochemical sys-
tem for investigating RA-inducible genes. F9 embryonal carci-
noma cells differentiate rapidly and synchronously into primi-
tive endoderm upon treatment with RA and into parietal
endoderm upon treatment with RA and cAMP analogs (19).
This model system has been used to identify retinoic acid
response elements (RAREs) controlling the expression of sev-
eral important developmental genes, such as Hoxa1 (20), lami-
nin B1 (21), and now Bmp2.
Here we describe the first genetic regulatory elements con-
trolling the RA-regulated induction of the Bmp2 gene in em-
bryonic cells. RA-regulated gene expression is mediated by
nuclear receptors, which act as retinoid-dependent transcrip-
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tion factors (22). Encoded by six different genes, RARa, -b, and
-g and RXRa, -b, and -g, the receptors can act as homodimers
and heterodimers, often with unique DNA binding and trans-
activation specificities (see Refs. 23 and 24). RARs bind to and
are activated by all-trans-RA and 9-cis-RA, while the RXRs are
activated only by 9-cis-RA. Our experiments in yeast suggest
that, like Hoxa1 and RARb, ligands that bind both RARs and
RXRs synergistically activate the Bmp2 promoter. The work
also suggests that, as in Drosophila, multiple transcription
start sites are utilized in different mammalian tissues.
EXPERIMENTAL PROCEDURES
F9 Cell Culture and Differentiation—F9 embryonal carcinoma cells
were grown in Dulbecco’s modified Eagle’s medium supplemented with
10% heat-inactivated calf serum and 2 mM glutamine. The cells were
induced to differentiate into primitive endoderm by adding RA alone
and into parietal endoderm by adding RA, 250 mM dibutyryl cAMP, and
500 mM theophylline (RACT).
Library Screen—Using two sets of primers (59-GAATTCCGGACT-
CAGGAGTG-39 and 59-CTCGAGACAGTCCAGCTGCG-39 (GenBankTM
accession number L25602)2; 59-AAACAGTAGTTTCCAGCAGC-39 and
59-TCTGATTCACTAACCTGGTG-39 polymerase chain reaction was
performed on amplified aliquots of a genomic library in l DASH II.
Polymerase chain reaction-positive aliquots were then screened (25)
with 32P-labeled probe from the full-length Bmp2 cDNA (pBMP2–452,
kindly provided by David Israel) or a Bmp2 subclone (pBMP2–68,
nucleotides 6,483–6,724 with respect to the translation start site) to
isolate two overlapping bacteriophage that contain the entire Bmp2
gene and extensive 59- and 39-flanking sequences (16.5 kilobases total).
lmBMP2–4771 contains the 59-flanking region of Bmp2 (nucleotides
28,583 to 13,360 relative to the translation start site). lmBMP2–1
contains the remainder of the transcribed region and the 39-flanking
region (nucleotides 2,979–15,700; see Fig. 2).
Plasmids—Plasmids were constructed as follows. All nucleotide po-
sitions are indicated with respect to the translation start site. For
pCAT59NN6.8 (28,583 to 22,320) and pCAT59NN6.3 (22,287 to
13,360), NotI fragments extending from NotI sites in l DASH II to each
of two genomic NotI sites from lmBMP2–4771 were filled with Klenow
fragment and ligated into the filled XbaI site in front of the pBLCAT2
Herpes simplex virus thymidine kinase (TK) minimal promoter (26).
For pCAT59XX4.5 (23,367 to 11,206), a XbaI fragment was ligated into
the XbaI site of pBLCAT2 in front of the pBLCAT2 TK promoter. For
pCAT39BB3.4 (9,318–12,700), a BamHI fragment from bacteriophage
lmBMP2–1 was filled and ligated into the SmaI site of pBLCAT2
downstream of the chloramphenicol acetyltransferase (CAT) coding
region. For pCAT39BN3.0 (12,700–15,700), a fragment downstream of
the Bmp2 gene was obtained by digesting bacteriophage lmBMP2–1 at
the genomic BamHI site and the l DASH II NotI site. The ends were
filled and ligated into the SmaI site of pBLCAT2 downstream of the
CAT coding region. For pCAT4.5X (23,367 to 21,658), a XbaI–XhoI
fragment was ligated into the XbaI and XhoI sites of the promoterless
vector, pBLCAT3 (26). For pCAT4.5XDNot (23,367 to 22,320; 22,287
to 21,658), two NotI sites at 22,320 and 22,288 in pCAT4.5X were
digested to remove a 32-bp fragment and religated. For pCAT59NB6.3B
(22,288 to 21,537), a NotI–BglII fragment was ligated into XbaI–BglII-
digested pBLCAT3 after filling the NotI and XbaI ends. For pBMP2-H
(22,231 to 21,232), a BamHI fragment was ligated into the BamHI site
of pBSIISK1 (Stratagene). For pBMP2-NX (22,289 to 21,658), a NotI–
XhoI fragment was ligated into the NotI and XhoI sites of pBSIISK1.
For pDss-BMP2 (23,367 to 21,658), a SalI–XhoI fragment from
pCAT4.5X was inserted into the XhoI site preceding the cyc1 promoter
in the yeast reporter plasmid pDss (27). For pDss-SN1.05 (23,367 to
22,316), a NotI–XhoI fragment in pDss-BMP2 was removed and reli-
gated after filling the ends. For pDss-BN.88 (23,195 to 22,316), a BglII
fragment from pGL-XN1.05 was inserted into the XhoI site of pDss after
partially filling the ends. For pGL-XN1.05 (23,364 to 22,316), a XbaI–
XhoI fragment from pCAT4.5X was inserted into the NheI and XhoI site
of pGL2 (Promega) to make pGL-XX1.7, and then a NotI–XhoI fragment
in pGL-XX1.7 was removed and religated after filling the ends. For
pDss-BB.83 (23,195 to 22,369), a BglII–BamHI fragment from
pCAT4.5X was inserted into the XhoI site of pDss after partially filling
the ends. For pDss-BB.06 (22,373 to 22,316), a BamHI–BglII fragment
from pGL-XN1.05 was inserted into the XhoI site of pDss after partially
filling the ends. For pDss-SB.18 (23,367 to 23,191), a BglII–XhoI frag-
ment in pDss-BMP2 was removed and religated after filling the ends.
Nuclear Run-on Assays—F9 cells were untreated or treated 72 h with
0.5 mM RA, dibutyryl cAMP, and theophylline as described above. Nu-
clei were isolated and nuclear run-on assays were performed as de-2 D. Israel, personal communication,
FIG. 1. Identification of the RA-in-
ducible Bmp2 promoter. F9 cells were
grown for 72 (A) or 96 h (B and C) in the
presence (RACT) or absence (Stem) of 0.5
(A) or 1 mM (B and C) RA and CT. A,
nuclear run-on assays. 32P-Labeled
probes generated from transcripts initi-
ated in these cells at the time of RNA
extraction were hybridized to identical ni-
trocellulose strips spotted with a vector
control (pGEM3Z) or plasmids containing
the cDNA encoding a constitutive riboso-
mal protein (36B4) or BMP2 (pBMP2–
452). B, ribonuclease protection assays.
Antisense probes extending from nucleo-
tide 21,541 to 21,233 and nucleotide
22,287 to 21,663 were hybridized to F9
cell RNA or to yeast tRNA, and ribonucle-
ase protection assays were performed.
The molecular weight marker (M) was
pBR322 digested with MspI. Visible frag-
ments are 622, 527, 404, 307, 242, 238,
217, 201, 190, 180, 160, 147, 123, and 110
bp in length. The positions of the undi-
gested probe and the protected fragment
are indicated by the thin and thick ar-
rows, respectively. The open arrow indi-
cates the predicted size of a fragment gen-
erated by the proximal promoter used in
osteoblast cells (36). C, primer extension
assays. An antisense oligonucleotide corre-
sponding to nucleotides 22,065 to 22,046
was hybridized to F9 cell RNA or to yeast
tRNA, and primer extension was per-
formed. One band was visible in the RACT
lane only. A sequence generated from this
oligonucleotide and pBMP2-NX is shown to
the left of the primer extension lanes.

















scribed previously (25, 28). Plasmids 36B4 (29), pGEM3Z (Promega),
and pBMP2–452 were used for hybridization.
Sequencing—Sequencing was performed manually (25), by the Mo-
lecular Biology Core Facility at the H. Lee Moffitt Cancer Center
(Tampa, FL) or by the DNA Sequencing Laboratory at the Interdisci-
plinary Center for Biotech Research (Gainesville, FL), using primers
from the vector and internal sequences. Analysis of the RA-responsive
upstream sequence for putative transcription factor binding sites was
performed using TFSEARCH3 versus the TFMATRIX transcription fac-
tor binding site profile data base (30) and by visual inspection. Promot-
erscan II4 was used to located putative promoter sequences (31).
Primer Extension—Primer extension was performed as described
previously (25). The primer 59-GTGGGAAGCGCAGCGGCGGC-39, cor-
responding to the complement of the sequence extending from 22,064
to 22,045, was labeled and hybridized to 29.7 mg of RNA and extended
with avian myeloblastosis virus reverse transcriptase (Life Technolo-
gies, Inc.).
Ribonuclease Protection Assays—Ribonuclease protection assays
were performed as described by Zinn et al. (32) with the following
modifications. 32P-Labeled RNA probes were made from pBMP2-H lin-
earized with BglII and transcribed with T3 RNA polymerase and
pBMP2-NX linearized with NotI and transcribed with T7 RNA polym-
erase. 106 cpm of each probe were hybridized to 10 mg of RNA overnight
at 45 °C in 80% deionized formamide, 40 mM PIPES, pH 8.5, 400 mM
NaCl, and 1 mM EDTA. After treatment with ribonuclease A, the
product was electrophoresed on a sequencing gel.
F9 Cell Transfections and CAT Assays—All methods were essentially
as described by Vasios et al. (21). F9 cells were cultured for 48 h without
drugs or in the presence of CT, RA, or RACT, transfected by calcium
phosphate precipitation, and then cultured an additional 24 or 48 h
with drugs. All cells were cotransfected with the reporter gene and with
pbAclacZ (21), which contains the b-galactosidase coding region driven
by the constitutive b-actin promoter. Cell extracts were normalized for
transfection efficiency as determined by b-galactosidase expression.
Equivalent amounts of extract were incubated at 37 °C for 7 h with 250
mM Tris, pH 7.8, 5.3 mM acetyl coenzyme A, and 32.4 mM 14C-chloram-
phenicol (51.5 mCi/mmol; NEN Life Science Products). After separation
by thin layer chromatography (Whatman No. 4410221), chloramphen-
icol acetylation was quantified with a Molecular Dynamics Phospho-
rImager or a Beckman 60001C liquid scintillation counter.
Yeast Transformations and b-Galactosidase Assays—The pDss b-ga-
lactosidase reporter vector (URA3) and the retinoid receptor expression
vectors p2HG-RARb (HIS3), pG1-RARg (TRP1), and pG1-RXRg (TRP1)
have been described (27, 33). The reporter vector and various receptor
expression vectors were used to transform the yeast strain BJ5409
(his3, leu2, trp1, ura3) using the lithium acetate method (34). Double or
triple transformants were selected by plating on synthetic medium
lacking the appropriate nutrients. For b-galactosidase assays, yeast
cells were grown in selective medium in the presence and absence of
retinoids for 24 h (all-trans-RA, Sigma; TTNPB and 9-cis-RA, Hoff-
man-La Roche; LG100268, Ligand Pharmaceuticals). The cells were ly-
sed, and b-galactosidase activity was assayed by o-phenylphosphogalac-
topyranoside hydrolysis at 30 °C (25). Normalized b-galactosidase values
were determined as follows: (A420/A600) 3 1,000/min of reaction time.
Electrophoretic Mobility Shift Assays—Electrophoretic mobility shift
assays were performed essentially as described by Ausubel et al. (25).
DNA probe was made by gel-purifying a 145-bp Sau3AI fragment
(22,372 to 22,227) from pCAT4.5X containing a Sp1 consensus se-
quence. The ends were filled in with Klenow fragment in the presence
of [32P]dCTP and [32P]dGTP. Binding reactions contained 1 unit of
rhSP1 (Promega), 60,000 cpm (2 ng) of probe, 10 mM HEPES, pH 7.9, 40
mM KCl, 6 mM MgCl2, 0.1% Triton X-100, 0.1 mM dithiothreitol, 0.25
mg/ml acetylated bovine serum albumin (New England BioLabs), 2%
Ficoll, and 0.05 mg/ml sonicated salmon sperm DNA (Sigma). Samples
were incubated for 30 min at room temperature and then loaded onto a
5% polyacrylamide gel (74:1 acrylamide:bisacrylamide, 5% glycerol (w/
v)). Electrophoresis was performed at 300 V for 45 min in 0.53 TBE at
4 °C. The gel was dried under vacuum onto filter paper (Whatman) and
exposed overnight to x-ray film (Eastman Kodak Co.).
RESULTS
Bmp2 Transcription in F9 Cells Increases in Response to
RACT Treatment—RNA abundance may be regulated by alter-
ations in transcription rate and in message stability. Previous
experiments using the transcriptional inhibitors actinomycin D
and 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole showed
that Bmp2 mRNA stability does not change with RA treatment
(35). This observation suggested, but did not prove, that RA
increased Bmp2 transcription rates. To test this hypothesis, we
isolated nuclei from untreated cells or cells treated with RACT
for 72 h and performed nuclear run-on assays (Fig. 1A). Bmp2
gene transcription increased 3.7-fold in RACT-treated cells rel-
ative to untreated cells. In contrast, the transcription of 36B4,
a constitutively expressed ribosomal protein, did not vary. This
directly demonstrated transcriptional induction of the Bmp2
3 TFSEARCH is available on the World Wide Web at http://pdap1.
trc.rwcp.or.jp/research/db/TFSEARCH.html.
4 Promoterscan II is available on the World Wide Web at http://biosci.
cbs.umn.edu/software/promoterscan.htm.
FIG. 2. Bmp2 gene structure and
CAT reporter constructs. A schematic
representation of the Bmp2 genomic se-
quence is shown. The sequence is num-
bered with respect to the translation start
site (36). Filled boxes represent exons
(36). D (distal) indicates transcription ini-
tiation from the RA-dependent promoter
in F9 cells, whereas P (proximal) indi-
cates the additional transcription initia-
tion site utilized in osteoblasts (37). The
bars below indicate the location and rela-
tive sizes of the sequences cloned into
CAT reporter vectors pBLCAT2 and
pBLCAT3. For pCAT59NN6.8, pCAT59-
XX4.5, and pCAT59NN6.3, fragments
were inserted 59 of the TK promoter in
pBLCAT2. For pCAT39BB3.4 and pCAT-
39BN3.0, fragments were inserted 39 of
the CAT coding region. For pCAT59-
NB6.3B, pCAT4.5X, and pCAT4.5XDNot,
fragments were inserted 59 of the CAT
coding region in the promoterless reporter
vector pBLCAT3.


















Location of the Transcription Start Site—Two Bmp2 promot-
ers have been described in osteoblast cells (36, 37). We used
ribonuclease protection assays to determine if these transcrip-
tion start sites or others were RA-inducible in F9 cells (Fig. 1B).
An antisense RNA probe that extended from nucleotide 21,541
to 21,233 relative to the translation initiation site was gener-
ated from pBMP2-H digested with BglII. The entire Bmp2
probe was protected by RNA isolated from RACT-treated cells
(Fig. 1B, thick arrow), indicating that Bmp2 transcription ini-
tiated upstream of nucleotide 21,541 in F9 cells. No protected
fragments were observed in the reactions containing RNA from
untreated cells, yeast tRNA (Fig. 1B), or a sense probe extend-
ing from 22,230 to 21,233 (data not shown). The open arrow
indicates the predicted location of a fragment generated by a
transcript originating at the proximal promoter (nucleotide
21,344) described by Feng et al. (36). The absence of a fragment
at this location indicates that, in contrast to osteoblast cells, this
promoter is not used in F9 cells. Using an antisense probe that
extended from 22,287 to 21,663 generated from pBMP2-NX, we
observed a fragment of approximately 493 nucleotides. This sug-
gests that transcription starts at approximately 22,156, near the
distal promoter used in osteoblasts.
To confirm the transcription start site, primer extension was
performed utilizing reverse transcriptase and a primer comple-
mentary to base pairs 22,064 to 22,045 relative to the trans-
lation start site (Fig. 1C). An extended product was detected
only in the reaction containing RNA from cells treated with 1
mM RA and CT for 96 h and not in the reactions containing RNA
FIG. 3. Regulation of Bmp2 reporter activity in F9 cells. F9 cells
were grown for 48 h in the absence of drug (Stem) or the presence of 1
mM RA (RA) or 250 mM dibutyryl cAMP and 500 mM theophylline (CT) or
all three drugs (RACT). Cells were then transfected with the plasmids
indicated under each group of bars and pbAclacZ, which contains a
constitutive promoter driving b-galactosidase. Reporter constructs con-
taining the TK promoter are shown in A; constructs without the TK
promoter are shown in B. 48 h later, cell extracts were made. b-Galac-
tosidase assays were performed to normalize for transfection efficiency.
Amounts of extract containing equivalent b-galactosidase activity were
then used for CAT assays. Each bar shows the average of 3–6 experi-
ments and the S.E. measurement.
FIG. 4. Regulation of Bmp2 reporter activity in yeast. Yeast
strain BJ5409 was transformed with expression vectors encoding RARb
or RARg alone or with RXRg as indicated under each bar (A and B) or
with RARb and RXRg (C). These yeast were subsequently transformed
with the empty reporter plasmid pDSS or pDSS-BMP2 as indicated
under each bar (A) or with pDSS-BMP2 (B and C). Cultures were
treated with the indicated retinoids at 1 mM. b-Galactosidase activities
and S.E. measurements are shown. n 5 3.

















from untreated cells or yeast tRNA. Comparison with the
genomic sequence designated a start site at nucleotide 22,127.
No other RACT-dependent extended products were observed,
suggesting utilization of one major transcriptional start site in
F9 cells. The differences in mobility between RNA and DNA
molecular weight markers explain the small discrepancy in
start site position as determined by primer extension or RNase
protection assays.
Regulation of Bmp2 Promoter Activity by RA in F9 Cells—
CAT assays were used to detect RA- or RACT-dependent in-
creases in CAT reporter activity driven by Bmp2 genomic DNA
in F9 cells. The reporter constructs containing sequence flank-
ing the Bmp2 gene are shown in Fig. 2. Since two transcrip-
tional start sites have been described (37), all nucleotide posi-
tions are indicated relative to the translational start site (Fig.
2). Several large regions of the Bmp2 upstream flanking region
were inserted upstream of the Herpes simplex virus TK mini-
mal promoter in pBLCAT2. These fragments, extending from
28,583 to 22,320 (pCAT59NN6.8), 23,367 to 11,206
(pCATXX4.5), and 22,287 to 13,360 (pCAT59NN6.3), failed to
drive CAT expression in F9 cells treated for 96 h with 1 mM RA
or 1 mM RA and CT (Fig. 3A). A fragment that included the
39-end of the transcribed region (9,316–12,700; pCAT39BB3.4)
did not affect CAT activity. In contrast, a fragment distal to the
39-end (12,700–15,700; pCAT39BN3.0) caused a 3.5–4-fold
CAT activation relative to the pBLCAT2 vector alone (Fig. 3A).
Since activation occurred in cells treated with CT, RA, or
RACT, this sequence must contain a non-RA-dependent regu-
latory element. Considering the highly tissue- and stage-spe-
cific expression of Bmp2, many regulatory elements are likely
to control Bmp2 expression.
Since developmental regulation of the dpp gene is mediated
by the core promoter (38), we hypothesized that the RA respon-
siveness of the Bmp2 gene was similarly controlled. If so, then
the TK minimal promoter in pBLCAT2 might have interfered
with RA-induced transcription. Therefore, Bmp2 sequences
were inserted into pBLCAT3, which lacks a minimal promoter.
A 1,709-bp fragment, containing nucleotides 23,367 to 21,658
(pCAT4.5X), induced CAT activity 2.8-fold in cells treated for
96 h with 1 mM RA or 1 mM RA and CT relative to the activity
observed in CT-treated cells (Fig. 3B). This fragment included
1,240 base pairs upstream of the transcription start site at
22,127. Finally, a fragment containing only 161 nucleotides
upstream of the transcriptional start site (22,288 to 21,537;
pCAT59NB6.3B) failed to induce CAT activity (Fig. 3B). These
results are consistent with the presence of elements required
for the RA response and promoter activity between nucleotides
23,367 and 22,288. As will be discussed below, we used a yeast
reporter system to further delineate this RARE.
A Bmp2 RARE Drives RA-dependent b-Galactosidase Ex-
pression in Yeast—It is difficult to distinguish genes regulated
directly by retinoid-activated receptors from those indirectly
activated by other transcription factors induced by RA in mam-
malian cells. To avoid the complications associated with endog-
enous receptors and other transcription factors in F9 cells, we
co-transformed yeast with mammalian receptor expression vec-
tors and reporter genes driven by Bmp2 genomic sequences.
Although yeast do not normally express retinoid receptors,
yeast transformed with receptor genes synthesize functional
receptors. These can stimulate the RA-dependent expression of
reporter genes controlled by mammalian RAREs (33, 39, 40).
We inserted a fragment containing base pairs 23,367 to 21,658
of the Bmp2 gene in front of the cyc1 promoter and the b-ga-
lactosidase coding region of the yeast vector, pDSS (27). The
yeast strain BJ5409 was transformed with this plasmid and
various combinations of RARb, RARg or RXRg yeast expression
vectors. Treatment of yeast expressing RARb or RARg and
RXRg with 1 mM all-trans-RA or 9-cis-RA induced b-galactosid-
ase activity 1.7- and 2.3-fold, respectively, relative to untreated
yeast (Fig. 4A). Yeast transfected with RARb or RARg alone
and treated with 9-cis-RA also induced b-galactosidase activity
1.6-fold, indicating that the RAR homodimers could activate
Bmp2 nearly as efficiently as the RAR/RXR heterodimer (Fig.
4B). In contrast, yeast expressing RXR alone or yeast lacking
receptors failed to express b-galactosidase in response to RA
treatment (Fig. 4B). These experiments indicate that the RA
responsiveness of this Bmp2 sequence in yeast requires activa-
tion of RAR homodimers or RAR/RXR heterodimers.
In addition to the naturally occurring all-trans-RA, which
activates only RARs, and 9-cis-RA, which activates both RARs
and RXRs, several synthetic receptor-selective retinoids are
available. TTNPB is often used to demonstrate RAR selectivity
in mammalian cells because, unlike all-trans-RA, it cannot be
converted to 9-cis-RA. LG100268 is an RXR-selective retinoid
(41). We treated RARb- and RXRg-expressing yeast with 1 mM
TTNPB, LG100268, or 9-cis-RA or the combination of TTNPB
and LG100268. Like all-trans-RA, TTNPB activated transcrip-
tion slightly (1.5-fold) but less effectively than 9-cis-RA (2.1-
fold, Fig. 4C). Interestingly, the RXR agonist induced activity
as effectively as the panagonist 9-cis-RA, which can activate
both the RARs and the RXRs. Combined exposure to these
retinoids stimulated activity by 3.6-fold (Fig. 4C). The syner-
gistic activation of several RA-responsive genes by simultaneous
ligand binding of each receptor subunit within a heterodimer has
also been observed in mammalian cells (42, 43). These results are
the first to demonstrate that the developmentally crucial Bmp2
gene is activated directly by retinoid-bound receptors.
Having proven that this sequence could drive the yeast b-ga-
lactosidase reporter gene in a ligand- and receptor-dependent
manner, we localized this element more precisely using a series
of deletion constructs (Fig. 5). Deletions of 39-flanking sequences
up to position 22,316 and 59-flanking sequences up to 22,373 do
FIG. 5. Deletion analysis of RA-re-
sponsive Bmp2 sequences in yeast.
Yeast strain BJ5409 was transformed
with expression vectors encoding RARb
and RARg. These yeasts were subse-
quently transformed with various por-
tions of Bmp2 genomic DNA driving the
b-galactosidase gene as indicated. Tran-
scriptional induction by 1 mM 9-cis-RA is
presented by -fold induction as indicated
in the histogram. “1-Fold” induction indi-
cates no difference in b-galactosidase ac-
tivity between untreated and RA-treated
cells. n 5 3. Bars show S.E.

















not alter the induction by 9-cis-RA (bars 1–4). The reporter
constructs containing only base pairs 23,195 to 22,369 or
23,367 to 23,191 were not induced by 9-cis-RA (bars 5–6). These
results indicate that a 57-bp Bmp2 promoter sequence located
between 22,373 and 22,316 bp contains a RARE that is neces-
sary and sufficient to induce RA-mediated transcription.
Sequencing and Analysis of the Upstream Region of the
Bmp2 Gene—We sequenced base pairs 23,367 to 21,658 of the
Bmp2 gene to identify consensus sequences for other known
regulatory proteins. Sequences consistent with a TATA-con-
taining promoter sequence and a transcription start site at
nucleotide 22,127 are depicted in Fig. 6. As shown in Fig. 1C,
the primer extension assay confirmed the activity of this pro-
moter in RACT-treated F9 cells. These features are consistent
with a promoter at this site.
The sequence was also scanned for putative regulatory pro-
tein binding sites. A putative Sp1 site was identified between
22,308 and 22,298 (Fig. 6). Since others have demonstrated
the importance of Sp1 sites for RA responsiveness (44–46), we
deleted a 32-bp fragment containing the site (Fig. 2). This
deletion failed to alter the magnitude of RA inducibility in
either yeast (data not shown) or F9 cells (Fig. 7A). However, in
F9 cells, both the basal and the induced transcription activity
of the CAT reporter gene declined by 30% (Fig. 7A). We also
demonstrated that recombinant Sp1 protein bound this se-
quence (Fig. 7B). These observations suggest that Sp1 influ-
ences the transcription activity of the Bmp2 gene but does not
play a role in RA responsiveness.
DISCUSSION
Approximately 200 genes have been shown to be RA-respon-
sive in one cell or another. Some genes are regulated directly by
RA-bound receptors, e.g. Hoxa1 (20), while others are second-
arily regulated by other transcription factors modulated in
RA-treated cells, e.g. Fgf4 (47). Since both retinoid deficiencies
and overdoses can cause embryonic malformations via the ab-
errant expression of key proteins controlling differentiation,
proliferation, apoptosis, and morphogenesis, it is important to
understand which genes are directly regulated. We now pres-
ent evidence that the gene encoding the essential growth and
differentiation factor, BMP2, is a direct target of RA.
Bmp2 is transcriptionally induced by RA in F9 embryonal
carcinoma cells (Fig. 1A). Several pieces of evidence suggest
that F9 cells utilize a Bmp2 promoter initiating transcription
at nucleotide 22,127 relative to the translation initiation site.
First, ribonuclease protection assays indicate that the longest
Bmp2 transcript initiates near this site (Fig. 1B). Second, this
FIG. 6. Nucleotide sequence of the
upstream region of the Bmp2 gene.
The sequence is numbered relative to the
translational start site. The start site
used in RA-treated F9 cells is indicated by
an arrow. The sequence sufficient for RA-
dependent activation in yeast is under-
lined. The Sp1 consensus sequence and a
putative TATA box are in boldface type.
The sequence complementary to the
primer extension oligonucleotide is shown
by a heavy underline.
FIG. 7. Sp1 protein binds a transcription activating sequence.
A, F9 cells were transfected with the reporter gene CAT driven by bp
23,367 to 21,658 (pCAT4.5X) or the same sequence lacking a 32-bp
fragment containing an Sp1 consensus sequence (pCAT4.5XDNot) as
described in the legend to Fig. 2. Cells were extracted 48 or 24 h after
transfection, resulting in 96 or 72 h of total exposure to drugs. The
activity of these reporter genes was induced 4.2- and 3.9-fold by RA.
However, both the induced and basal activity of the fragment lacking
the Sp1 site was reduced approximately 30%. Bars show the range; n 5
2. B, a 145-bp fragment containing the Sp1 site (22,372 to 22,227) was
end-labeled with 32P-dCTP and 32P-dGTP and bound to recombinant
human Sp1. Lane 1 indicates the migration of free probe (open arrow).
Lane 2 shows the retardation caused by binding of the DNA fragment to
the unglycosylated (95-kDa) and glycosylated (105-kDa) forms of Sp1
(closed arrows).

















is the end of an RA-inducible primer extension product (Fig.
1C). Third, the predicted size of a transcript starting at 22,127
is consistent with the mRNA size of 3.8 kilobases (17, 36).
Finally, sequences resembling a TATA-containing promoter
are near nucleotide 22,127 (31).
In mouse osteoblasts, distal and proximal transcription start
sites were observed at nucleotides 22,127 and 21,344 (36, 37).
We did not observe a ribonuclease protection fragment corre-
sponding to the proximal start site in untreated or in RACT-
treated F9 cells (Fig. 2B). Thus, the proximal promoter does not
mediate the RA-induced transcription of Bmp2 in F9 cells. The
existence of multiple Bmp2 transcription start sites in different
cell types is not surprising, because the expression of the Bmp2
gene is highly dynamic. In addition, dpp, the gene encoding the
Drosophila homolog of Bmp2, has three major and several
minor transcripts produced from several promoters (15). Like
the dpp transcript, the Bmp2 transcript has an unusually long
59-untranslated region of 1,125 nucleotides that might contain
as yet uncharacterized regulatory elements. Since Bmp2 and
dpp are pivotal developmental genes, their spatial and tempo-
ral expression must be tightly regulated. We have demon-
strated here that tissue-specific promoters are one mechanism
involved in this tight regulation.
We have shown that this promoter and 1,709 base pairs of
flanking region drive RA-dependent reporter gene expression
in F9 cells. RA, which induces primitive endoderm differentia-
tion, and RA and CT (dibutyryl cyclic AMP and theophylline),
which induce parietal endoderm differentiation, caused equal
activation of the CAT reporter gene (Fig. 3B). The endogenous
Bmp2 RNA is undetectable in undifferentiated cells and is
induced modestly in RA-treated cells. In contrast, although CT
does not induce differentiation and has no effect on Bmp2
mRNA abundance, the combination of RA and CT induces the
message abundance strikingly. Thus, sequence outside of
23,367 to 21,658 must contain the elements responsible for
the synergistic activity of RA and cAMP.
Our demonstration that a 57-bp fragment of Bmp2 genomic
DNA can drive the expression of a b-galactosidase reporter
gene in yeast transformed with retinoid receptors strongly
suggests that this gene is directly regulated by receptor bind-
ing. The RAR/RXR heterodimer in the presence of ligands that
activate both subunits activated the Bmp2-driven reporter
most efficiently (Fig. 4C). Similar synergy has been observed
for many genes in mammalian cells, including Hoxa1 and the
RARb gene (42, 43). A requirement for specific receptor combi-
nations and specific ligand activities may mediate the tight
regulation of developmentally crucial genes such as Bmp2.
Known retinoic acid-responsive elements are highly poly-
morphic and conform loosely to the form of two repeated half-
sites separated by nonconserved “spacer” DNA: RG(G/T)-
TCAN5RG(G/T)TCA (22). Although the most frequent forms
are direct repeats separated by 5 base pairs (N), some RAREs
consist of inverted repeats, much wider spacing, and diverse
arrangements of half-sites. Since the 57-bp Bmp2 RARE lacks
identity to any previously described RAREs, point mutational
analyses will be necessary to identify the precise sequences
bound by retinoid receptors. Considering that the numerous
combinations of the six retinoid receptors and their various
isozymes have distinct ligand- and DNA-binding specificities
and that over 200 genes are known to be modulated in retinoid-
treated cells (48), many more types of functional RAREs are
likely to be found.
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